

REMARKS

Claims 65 and 67-93 are pending. In the Office Action mailed May 22, 2006, the Examiner set forth an election of species requirement pursuant to 35 USC 121. The Examiner asserts that the claims are directed to the following patentably distinct species: treatment of the following conditions: T-cell mediated immune response, an inflammatory disease or disorder (including inflammation), autoimmune disease or disorder, graft vs. host disease, and allergy or asthma.

Applicants hereby elect to have examined claims directed to treatment of an inflammatory disease or disorder (including inflammation). It is believed that claims 67-76 are readable on the elected embodiments of the invention.

Respectfully submitted,
GENENTECH, INC.

Date: November 22, 2006

By: *Diane L. Marschang*
Diane L. Marschang
Reg. No. 35,600
Telephone No. (650) 225-5416